Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 209.00
Bid: 208.00
Ask: 215.00
Change: -6.00 (-2.79%)
Spread: 7.00 (3.365%)
Open: 212.00
High: 214.00
Low: 207.00
Prev. Close: 215.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
3rd May 20172:00 pmRNSPureTech's Gelesis Receives Eur2.9 Million Award
2nd May 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Apr 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
13th Apr 20177:05 amRNSPDMR DEALING - PURCHASE OF SHARES
13th Apr 20177:00 amRNSDirector/PDMR Shareholding
11th Apr 20177:00 amRNSPureTech Advances New Immuno-oncology Programme
10th Apr 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th Apr 20177:00 amRNSPureTech's Akili Announces Pilot Study Results
6th Apr 20177:00 amRNSFinal Results
24th Mar 20177:00 amRNSPureTech Announces Novartis Licensing Agreement
14th Mar 20177:00 amRNSNotice of Results
8th Mar 20177:00 amRNSPureTech Capital Markets Meeting in London 9 May
2nd Mar 20177:00 amRNSPureTech Appoints Bharatt Chowrira as President
24th Feb 20177:00 amRNSPureTech to Present at Cowen & Co. Conference
23rd Feb 20177:00 amRNSPureTech Health Appoints Atul Pande as CMO
16th Feb 20177:00 amRNSPureTech's Vedanta Announces 2 New Collaborations
7th Feb 20177:00 amRNSPureTech to Present at Leerink Conference
22nd Dec 20167:00 amRNSDirector/PDMR Shareholding
20th Dec 20164:53 pmRNSResearch Update: Two Studies from Tal Medical
15th Dec 20167:00 amRNSResearch Update: PureTech's Karuna data positive
9th Dec 20164:30 pmRNSPureTech's Akili and Pfizer Present Positive Data
4th Nov 20167:00 amRNSPureTech's Gelesis Presents Data at ObesityWeek
2nd Nov 20167:00 amRNSPureTech to Present at Jefferies Conference
20th Oct 20167:00 amRNSPureTech Appoints Joseph Bolen as CSO
19th Oct 20167:00 amRNSPureTech's Vedanta Granted European Patent
3rd Oct 201612:07 pmRNSSecond Price Monitoring Extn
3rd Oct 201612:02 pmRNSPrice Monitoring Extension
27th Sep 20167:00 amRNSDirector/PDMR Shareholding
21st Sep 20167:00 amRNSAkili's Project:EVO Identifies Cognitive Deficits
12th Sep 20167:00 amRNSKaruna Doses First Subject in Tolerability POC
7th Sep 20167:00 amRNSHalf-year Report
6th Sep 20167:00 amRNSVedanta Biosciences Granted Third U.S. Patent
2nd Sep 20167:00 amRNSGelesis Appoints New Chief Operating Officer
23rd Aug 20167:00 amRNSNotice of Results
23rd Aug 20167:00 amRNSVedanta Biosciences Granted Second U.S. Patent
16th Aug 20167:00 amRNSPureTech's Vedanta Biosciences Granted US Patent
11th Aug 20167:00 amRNSVedanta and NYU Langone Medical Center Collaborate
27th Jul 20164:24 pmRNSHolding(s) in Company
22nd Jul 20167:00 amRNSHolding(s) in Company
20th Jul 20167:00 amRNSTwo Pharma Funds Invest in PureTech's Akili
12th Jul 20163:00 pmRNSDirector/PDMR Shareholding
8th Jul 20167:00 amRNSPureTech Appoints Feng Zhang to SAB & Expands Team
28th Jun 20167:00 amRNSPureTech's Sonde Advances Vocal Biomarker Platform
24th Jun 20163:00 pmRNSDaphne Zohar 2016 EY Entrepreneur Of The Year
6th Jun 20167:00 amRNSVedanta Biosciences Raises $50 Million
1st Jun 20164:30 pmRNSTopline Data from Tal Medical LFMS Study
31st May 20161:00 pmRNSPureTech to present at Jefferies Conference
20th May 20164:20 pmRNSHolding(s) in Company
20th May 20164:20 pmRNSDirector/PDMR Shareholding
20th May 20164:12 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.